Literature DB >> 1769693

Murine immune response to HIV-1 p24 core protein following subcutaneous, intraperitoneal and intravenous immunization.

L Fyfe1, J Maingay, A C Robinson, S E Howie.   

Abstract

The murine immune response to baculovirus-produced human immunodeficiency virus type-1 (HIV-1)p24 was examined after injection by three different routes: subcutaneously (s.c.), intraperitoneally (i.p.) and intravenously (i.v.). Both antigen-specific T-cell proliferation and serum antibody were induced by i.p. injection. In contrast, s.c. and i.v. injection of antigen resulted in specific antibody generation alone. Lympho-proliferative responses seen after i.p. injection were confined to splenocytes, and were greater after a low dose of antigen than after a high dose. p24-specific proliferation was not detected in lymph node cells. CD4:CD8 ratios were normal in lymph nodes and spleen at all times, irrespective of the dose or route of administration. p24-specific serum IgG antibodies were detected in all animals after the second injection of antigen. After s.c. and i.v. administration of high doses of antigen, the median antibody titres continued to rise after a third injection, but plateaued in animals injected by the i.p. route. In contrast, low doses of antigen given i.p. increased the median titre during and after the course of four injections. A low antigen dose given s.c. resulted in a plateau of median titre between the third and fourth injections. In i.v.-injected animals the median titre decreased between the third and fourth injections. IgG1 p24-specific antibodies were detected in all immunized mice, whereas IgM antibodies were detectable only following i.p. injection of antigen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1769693      PMCID: PMC1384641     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  14 in total

Review 1.  B-cell activation and HIV-1 infection: deeds and misdeeds.

Authors:  A Amadori; L Chieco-Bianchi
Journal:  Immunol Today       Date:  1990-10

Review 2.  Immunologic issues in anti-retroviral therapy.

Authors:  R Yarchoan; H Mitsuya; S Broder
Journal:  Immunol Today       Date:  1990-09

3.  Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

Authors:  J M Lange; D A Paul; H G Huisman; F de Wolf; H van den Berg; R A Coutinho; S A Danner; J van der Noordaa; J Goudsmit
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

4.  Suppression.

Authors:  N A Mitchison
Journal:  Immunol Today       Date:  1989-12

5.  Protective immunisation against hepatitis B with an internal antigen of the virus.

Authors:  K Murray; S A Bruce; P Wingfield; P van Eerd; A de Reus; H Schellekens
Journal:  J Med Virol       Date:  1987-10       Impact factor: 2.327

Review 6.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Authors:  A S Fauci
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

7.  Induction of suppressor cells and cells producing antigen-specific suppressor factors by haptens bound to self carriers.

Authors:  W Ptak; D Rózycka; M Rewicka
Journal:  Immunobiology       Date:  1980-01       Impact factor: 3.144

8.  Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS.

Authors:  J Schüpbach; O Haller; M Vogt; R Lüthy; H Joller; O Oelz; M Popovic; M G Sarngadharan; R C Gallo
Journal:  N Engl J Med       Date:  1985-01-31       Impact factor: 91.245

9.  Expression and purification of p24, the core protein of HIV, using a baculovirus-insect cell expression system.

Authors:  H R Mills; I M Jones
Journal:  AIDS       Date:  1990-11       Impact factor: 4.177

10.  Protection against hepatitis B virus infection by immunization with hepatitis B core antigen.

Authors:  S Iwarson; E Tabor; H C Thomas; P Snoy; R J Gerety
Journal:  Gastroenterology       Date:  1985-03       Impact factor: 22.682

View more
  1 in total

1.  Peripheral T lymphocyte depletion by apoptosis after CD4 ligation in vivo: selective loss of CD44- and 'activating' memory T cells.

Authors:  S E Howie; A J Sommerfield; E Gray; D J Harrison
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.